Vitamin D and vitamin D receptor polymorphism in Asian adolescents with primary dysmenorrhea.
Adolescents
Asian
Primary dysmenorrhea
Vitamin D
Vitamin D receptor
Journal
BMC women's health
ISSN: 1472-6874
Titre abrégé: BMC Womens Health
Pays: England
ID NLM: 101088690
Informations de publication
Date de publication:
05 08 2023
05 08 2023
Historique:
received:
20
01
2023
accepted:
24
07
2023
medline:
7
8
2023
pubmed:
6
8
2023
entrez:
5
8
2023
Statut:
epublish
Résumé
The expression of vitamin D receptor in the normal endometrium and ovaries supports the role of vitamin D in local immunity and inflammatory cytokines regulation. This study aimed to detect the relation between serum 25(OH)D and primary dysmenorrhea in Asian Adolescents. Two hundred and five (205) adolescents complaining of primary dysmenorrhea (study group) were compared in this prospective study to matched controls (210 controls) after informed consent following the Helsinki Declaration. After thorough evaluation, including a thorough history and pelvic ultrasound examination, blood samples were collected from the studied adolescents to measure serum 25(OH)D and for vitamin D receptor TaqI (rs731236) genotyping. The studied adolescents' data were analyzed using the Pearson's correlation to detect the relation between serum 25(OH)D and primary dysmenorrhea (primary outcome). The secondary outcome measures the odds of primary dysmenorrhea in Asian adolescents with vitamin D receptor TaqI (rs731236) polymorphism. The serum 25(OH)D was significantly lower in the studied-dysmenorrhea group compared to controls (16.17 ± 7.36 versus 17.65 ± 6.36 ng/ml, respectively), (P = 0.01). The correlation analysis showed a significant negative correlation between the serum 25(OH)D and visual analogue scale of dysmenorrhea (r = -0.9003, P < 0.0001). The studied-dysmenorrhea cases with vitamin D receptor T/t and t/t genotypes had significantly lower serum 25(OH)D (16.7 ± 8.05 and 14.4 ± 4.1 ng/ml, respectively) compared to controls (18.97 ± 6.7 and 21.4 ± 2.45 ng/ml, respectively), (P = 0.02 and 0.004, respectively). The VDR T/t and t/t polymorphisms significantly increase the odds of primary dysmenorrhea (OR 1367.2, P < 0.0001 and OR 106.2, P = 0.001, respectively). The serum 25(OH)D was significantly lower in the studied-dysmenorrhea group compared to controls. The studied-dysmenorrhea cases with VDR T/t and t/t TaqI genotypes had significantly lower serum 25(OH)D compared to controls. The VDR T/t and t/t polymorphisms significantly increase the odds of primary dysmenorrhea.
Sections du résumé
BACKGROUND
The expression of vitamin D receptor in the normal endometrium and ovaries supports the role of vitamin D in local immunity and inflammatory cytokines regulation.
OBJECTIVE
This study aimed to detect the relation between serum 25(OH)D and primary dysmenorrhea in Asian Adolescents.
METHODS
Two hundred and five (205) adolescents complaining of primary dysmenorrhea (study group) were compared in this prospective study to matched controls (210 controls) after informed consent following the Helsinki Declaration. After thorough evaluation, including a thorough history and pelvic ultrasound examination, blood samples were collected from the studied adolescents to measure serum 25(OH)D and for vitamin D receptor TaqI (rs731236) genotyping. The studied adolescents' data were analyzed using the Pearson's correlation to detect the relation between serum 25(OH)D and primary dysmenorrhea (primary outcome). The secondary outcome measures the odds of primary dysmenorrhea in Asian adolescents with vitamin D receptor TaqI (rs731236) polymorphism.
RESULTS
The serum 25(OH)D was significantly lower in the studied-dysmenorrhea group compared to controls (16.17 ± 7.36 versus 17.65 ± 6.36 ng/ml, respectively), (P = 0.01). The correlation analysis showed a significant negative correlation between the serum 25(OH)D and visual analogue scale of dysmenorrhea (r = -0.9003, P < 0.0001). The studied-dysmenorrhea cases with vitamin D receptor T/t and t/t genotypes had significantly lower serum 25(OH)D (16.7 ± 8.05 and 14.4 ± 4.1 ng/ml, respectively) compared to controls (18.97 ± 6.7 and 21.4 ± 2.45 ng/ml, respectively), (P = 0.02 and 0.004, respectively). The VDR T/t and t/t polymorphisms significantly increase the odds of primary dysmenorrhea (OR 1367.2, P < 0.0001 and OR 106.2, P = 0.001, respectively).
CONCLUSION
The serum 25(OH)D was significantly lower in the studied-dysmenorrhea group compared to controls. The studied-dysmenorrhea cases with VDR T/t and t/t TaqI genotypes had significantly lower serum 25(OH)D compared to controls. The VDR T/t and t/t polymorphisms significantly increase the odds of primary dysmenorrhea.
Identifiants
pubmed: 37543584
doi: 10.1186/s12905-023-02569-9
pii: 10.1186/s12905-023-02569-9
pmc: PMC10403873
doi:
Substances chimiques
Receptors, Calcitriol
0
Vitamin D
1406-16-2
VDR protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
414Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Asian Pac J Cancer Prev. 2019 Jul 01;20(7):2065-2072
pubmed: 31350967
Obstet Gynecol Sci. 2019 Mar;62(2):73-86
pubmed: 30918875
Hum Reprod Update. 2015 Nov-Dec;21(6):762-78
pubmed: 26346058
Obstet Gynecol. 2018 Dec;132(6):e249-e258
pubmed: 30461694
Gynecol Endocrinol. 2019 Jan;35(1):53-57
pubmed: 30044160
Epidemiol Rev. 2014;36:104-13
pubmed: 24284871
Prz Menopauzalny. 2022 Jun;21(2):81-91
pubmed: 36199743
BMC Womens Health. 2023 Mar 27;23(1):138
pubmed: 36973702
Gynecol Endocrinol. 2017;33(sup1):52-55
pubmed: 29264978
Acta Biomed. 2017 Jan 16;87(3):233-246
pubmed: 28112688
Taiwan J Obstet Gynecol. 2018 Feb;57(1):58-63
pubmed: 29458904
Eur J Obstet Gynecol Reprod Biol. 2018 Oct;229:190-194
pubmed: 30216855
Open Access Rheumatol. 2014 May 08;6:39-47
pubmed: 27790033
Gynecol Endocrinol. 2018 Aug;34(8):659-663
pubmed: 29447494
J Gene Med. 2021 Dec;23(12):e3386
pubmed: 34365691
Gynecol Minim Invasive Ther. 2022 Sep 16;11(4):209-214
pubmed: 36660333
Am J Obstet Gynecol. 2014 Apr;210(4):347.e1-347.e10
pubmed: 24262718
Obstet Gynecol Sci. 2021 Jan;64(1):13-26
pubmed: 33406811
J Clin Endocrinol Metab. 2011 Jul;96(7):1911-30
pubmed: 21646368
Arch Intern Med. 2012 Feb 27;172(4):366-7
pubmed: 22371927
J Mol Endocrinol. 2006 Jun;36(3):415-24
pubmed: 16720713
Prz Menopauzalny. 2020 Mar;19(1):1-5
pubmed: 32508549
Prz Menopauzalny. 2020 Dec;19(4):179-183
pubmed: 33488329
Acta Obstet Gynecol Scand. 2022 Dec;101(12):1364-1373
pubmed: 36124820
Bone. 2009 Dec;45(6):1091-7
pubmed: 19647104
PLoS One. 2015 Jul 28;10(7):e0134187
pubmed: 26218569
PLoS One. 2014 Jan 30;9(1):e87292
pubmed: 24498064
Nutr Health. 2018 Dec;24(4):269-278
pubmed: 30296903
Rev Bras Ginecol Obstet. 2020 Aug;42(8):501-507
pubmed: 32559803
J Turk Ger Gynecol Assoc. 2018 Feb 02;19(3):128-131
pubmed: 29391329
Reprod Sci. 2007 Jul;14(5):486-97
pubmed: 17913968
Obstet Gynecol Sci. 2021 Jul;64(4):353-363
pubmed: 34010550
Contraception. 2010 Mar;81(3):185-96
pubmed: 20159173
J Natl Med Assoc. 2018 Feb;110(1):78-83
pubmed: 29510848
Maturitas. 2015 Jun;81(2):256-65
pubmed: 25882760